Ann: Lumos and BARDA Partnership - Investor Presentation, page-3

So what I gathered:

- No intent for a takeover from Doug's understanding and not something which RYD or TM typically do.
- There could be (but not guaranteed) further support from the US Government in bulk purchases of Febridx similar to what occurred with Covid to support the combating of antimicrobial resistance.
- Payments for the award (which is not repayable to BARDA) are based on milestones. These include establishing the test, initial patient in the test and completion of the test.
- The initial $3Million covers this. The remaining option will be to support expanding the CLIA waiver further to the under 12 age bracket, currently it is only available for 12-64 years of age.


More importantly:

This is the only test of its kind in the setting available. If I heard correctly, BARDA funding/budget was for $20Million specifically for Anti Microbial Resistance. Lumos has been granted nearly 50% of that funding.